In the treatment of epilepsy, the role played by ADP-ribosylcyclase (ADPRC) and lysophosphatidic acid receptor 3 (LPAR3) as components of Ca2+ influx pathways has yet not been demonstrated. Here, LPAR3 is linked to epilepsy.